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Abstract
Background
Telemonitoring, the use of communication technology to remotely monitor health status, is an appealing
strategy for improving disease management.
Methods and Results
We searched Medline databases, bibliographies, and spoke with experts to review the evidence on
telemonitoring in heart failure patients. Interventions included: telephone-based symptom monitoring (n =
5), automated monitoring of signs and symptoms (n = 1), and automated physiologic monitoring (n = 1).
Two studies directly compared effectiveness of 2 or more forms of telemonitoring. Study quality and
intervention type varied considerably. Six studies suggested reduction in all-cause and heart failure
hospitalizations (14% to 55% and 29% to 43%, respectively) or mortality (40% to 56%) with telemonitoring.
Of the 3 negative studies, 2 enrolled low-risk patients and patients with access to high quality care, whereas 1
enrolled a very high-risk Hispanic population. Studies comparing forms of telemonitoring demonstrated
similar effectiveness. However, intervention costs were higher with more complex programs ($8383 per
patient per year) versus less complex programs ($1695 per patient per year).
Conclusion
The evidence base for telemonitoring in heart failure is currently quite limited. Based on the available data,
telemonitoring may be an effective strategy for disease management in high-risk heart failure patients.
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Abstract
Background— Telemonitoring, the use of communication technology to remotely monitor health
status, is an appealing strategy for improving disease management.
Methods— We searched Medline databases, bibliographies, and spoke with experts to review the
evidence on telemonitoring in heart failure patients.
Results— Interventions included: telephone-based symptom monitoring (n=5), automated
monitoring of signs and symptoms (n=1), automated physiologic monitoring (n=1). Two studies
directly compared effectiveness of 2 or more forms of telemonitoring. Study quality and intervention
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type varied considerably. Six studies suggested reduction in all-cause and heart failure
hospitalizations (14% to 55% and 29% to 43%, respectively) or mortality (40% to 56%) with
telemonitoring. Of the 3 negative studies, 2 enrolled low-risk patients and patients with access to
high quality care while 1 enrolled a very high risk Hispanic population. Studies comparing forms of
telemonitoring demonstrated similar effectiveness. However, intervention costs were higher with
more complex programs ($8383 per patient per year) versus less complex programs ($1695 per
patient per year).
Conclusions— The evidence base for telemonitoring in heart failure is currently quite limited.
Based on the available data, telemonitoring may be an effective strategy for disease management in
high-risk heart failure patients.
INTRODUCTION
Telemonitoring, the use of communication technology to monitor patients’ clinical status, is
gaining attention as a strategy to improve the care of patients with chronic disease. By allowing
clinical data to be collected without the need for face-to-face contact with patients,
telemonitoring can make care more accessible for patients and has the potential to improve
outcomes. The Institute of Medicine’s endorsement of this approach is evident, as the first of
its 10 rules for redesigning the health care system outlined in the report, “Crossing the Quality
Chasm” (1) is “Patients should receive care whenever they need it and in many forms, not just
face-to-face visits.”
Telemonitoring holds particular promise for patients with heart failure, who often experience
deterioration in their health status with an increase in weight and symptoms over a period of
days and weeks before presenting to medical attention and requiring hospitalization. A system
of frequent monitoring could alert clinicians to the early signs and symptoms of
decompensation, providing the opportunity for intervention before patients become severely
ill and require hospitalization. Moreover, patients’ participation in communicating information
about their weight and health status on a daily basis could have a favorable effect on their health
behaviors, including adherence to medical recommendations.
The importance of telemonitoring is highlighted by national efforts to disseminate this
approach. Telemonitoring is being used to care for patients with a variety of chronic conditions
in the Veterans Affairs healthcare system (2,3) and in some managed care settings (4). The
Centers for Medicare and Medicaid Services is implementing widespread demonstration
projects that mandate the use of remote monitoring technologies to enable the exchange of
pertinent clinical information, such as vital signs and symptoms (5). Up to 300,000 patients
with heart failure, complex diabetes and chronic obstructive pulmonary disease will be
enrolled, and the interventions may eventually be implemented nationally. Previous reviews
of telemonitoring in heart failure (6,7) have not provided an in-depth exploration of the details
of each intervention, a necessary step in understanding which components make a program
effective. Unless the following critical issues are made transparent, telemonitoring will remain
poorly understood:
1. What did the telemonitoring program consist of?
2. Who was responsible for acting on the information obtained?
3. How was the intensity and duration of the program modulated to meet the clinical
needs of patients?
4. What are the costs of implementing the telemonitoring program and what effect did
the program have on health care costs?
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These reviews also limited their analyses to studies of rather sophisticated forms of
telemonitoring: studies in which the intervention was based purely on telephone monitoring
were not included. We sought to extend the results of these prior reviews of telemonitoring in
heart failure by performing an in-depth examination of a wide range of telemonitoring
interventions with the addition of several recently published studies not previously analyzed
(8–10).
METHODS
We chose to group studies according to the primary mode of the telemonitoring intervention
as this is a defining feature. The primary mode of intervention (telephone-based symptom
monitoring, automated monitoring of signs and symptoms, automated physiologic monitoring,
and comparisons of 2 or more methods) thus serves as the basis for the sub-group analyses in
the Results section.
Evidence Acquisition
Studies for this review were obtained from Ovid MEDLINE and EMBASE searches
(performed August 20, 2006 with the assistance of a professional librarian) of English language
literature from 1966 to August 2006. We used the MESH term heart failure, congestive and
text word variations combined with any of the following MESH terms and their text word
variations: telemedicine, telecommunication, telecare, telehealth, telenursing,
telemanagement, telecardiology, teleconsult, telediagnosis, remote diagnosis, remote consult,
remote monitor. This search resulted in 97 articles.
Inclusion Criteria
In selecting studies for inclusion in this review, we required that studies use home
telemonitoring for adult patients with heart failure and that they assess hospitalization or
mortality rates. We also required a randomized study design. In an effort to obtain data that
may be available but not published, we contacted primary study authors if outcomes of interest
were not available in the published report.
Telemonitoring spans a gamut of modalities, ranging from simple telephone systems to
sophisticated systems of physiologic monitoring. Although some authors have chosen to
narrowly define it as “telephone plus” interventions (6,7), the Institute of Medicine defines
telemonitoring more broadly as “the use of electronic information and communications
technologies to provide and support health care when distance separates the
participants.” (11) As there is no clear rationale for excluding telephone systems, they are
included here. For the purposes of this review, we excluded studies that had in-person, face-
to-face components to the monitoring intervention, since our goal was to synthesize the
evidence for remote monitoring of heart failure patients.
Data Extraction
One of the investigators (SIC) reviewed all abstracts retrieved by the literature search. Abstracts
needed to appear potentially relevant to the study area and 63 were deemed not relevant. Two
investigators (SIC and CP) then independently assessed each article to determine its
appropriateness for inclusion. We searched the bibliographies of all studies retrieved from our
original search for additional relevant work, also including articles suggested by experts in the
field. This search strategy yielded 9 studies that were included in this review. Given the
heterogeneity among studies in nature of intervention, study population, duration of follow-
up, and outcomes assessed, we made an a-priori decision not to pool results from individual
studies.
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Quality Assessment
Quality assessment of telemonitoring trials is challenging as many of the widely used quality
scales emphasize study participant blinding, which is not possible in this type of trial (12). In
assessing quality of trials in this review, we used criteria suggested by Juni et al (13) as well
as those recommended by the York Centre for Reviews and Dissemination (14). These methods
yielded a total of 6 criteria by which we assessed the quality of studies.
RESULTS
Of the 9 studies included in this review, 2 were conducted at a single site and 8 were conducted
within the United States.
Evidence Synthesis
Telephone-Based Symptom Monitoring—The 5 studies in this category all employed
an intervention based upon symptom monitoring by nurses via live one-on-one telephone calls
with patients. Despite having this basic feature in common, the studies differ widely in design,
including who was responsible for initiating management changes, the complexity of the
intervention and patient population enrolled.
In the DIAL trial (10), patients received telephone-based monitoring and education from
centralized nurses trained in the management of heart failure. The intervention was based on
5 objectives: symptom monitoring, adherence to diet and medications, optimal fluid status, and
daily physical activity. Nurses used a software program to determine call frequency (calls
occurred every 2 weeks for 8 weeks then at a variable frequency). If clinical deterioration was
detected, the nurses used a standardized algorithm to adjust diuretic doses or recommend urgent
medical visits. There was a 20% relative risk reduction in the primary, combined outcome of
heart failure hospitalizations and death (95% Confidence Interval (CI) 3–34), which was
largely due to reductions in heart failure hospitalization.
The intervention employed by Dunagan et al (17) was similar to the DIAL intervention.
Centralized nurses trained in the management of heart failure made calls to promote self-
management skills. Though the intervention was telephone-based, 20 patients also received
home visits for additional support initially. During the calls (which occurred weekly for 2 weeks
and then according to individual patients’ needs), nurses also screened for evidence of heart
failure decompensation and, based on clinical judgment, could advise the patients to take
supplemental diuretic doses. A 47% reduction was seen in the primary outcome of all-cause
hospitalization or emergency room visits (95% CI 0.36–0.80). Of note, the investigators
prematurely terminated the planned enrollment of 500 patients after 151 patients due to
logistical and financial constraints.
In the study by Riegel et al, registered nurses monitored patients’ clinical status and educated
them about heart failure. (16). The frequency of calls was determined by nurses using decision
support software. The software also set priorities for patient education and was designed to
emphasize adherence and recognition of worsening illness. While symptom monitoring was
performed, clinical management was deferred to patients’ physicians, who were sent reports
on patients’ status. A 50% reduction was seen in the primary outcome of heart failure
hospitalizations (95% CI 0.35–0.73). The program was found to be cost-saving: the average
cost of acute care was $1000 less per patient in the intervention group (compared with the usual
care group) over 6 months and the 6 month intervention cost was $443 per patient.
In a separate study also by Riegel et al, (18) the same intervention used in this group’s prior
study (16) was implemented in a group of Hispanics of Mexican origin who were hospitalized
with heart failure. The intervention was refined to be culturally appropriate, with more
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emphasis on contacts with the family. The study sample was poorly educated (78% less than
high school education) and mostly unacculaturated into U.S. society (55%). In this study, no
significant differences were found in the primary outcome of heart failure hospitalizations
In the DeBusk study (9) centralized nurses performed symptom monitoring, heart failure
education and pharmacologic management. Nurse case-managers also initiated and regulated
medications for heart failure according to study protocol. In addition to scheduled calls (which
occurred weekly for 6 weeks and then at a decreased frequency), nurse judgment was used to
determine need for supplemental calls and to tailor content to individual patient needs. This
study is notable as one of the few in the heart failure disease management literature to
demonstrate no benefit: the relative risk (RR) for heart failure hospitalization was 0.91 (95%
CI 0.71–1.16) and the RR for all-cause hospitalization was 0.98 (95% CI 0.76–1.27).
Studies in this category are recent, large-scale and of high quality. Three of the 5 trials
demonstrated decreased heart failure hospitalization rates and 2 demonstrated decreased all-
cause hospitalizations. Eligibility proportions range from 0.20–0.64 with the DIAL trial having
the highest proportion. Only the study done in 2002 by Riegel (16) included an economic
analysis comparing cost with financial savings and demonstrated cost benefit of the program.
While all studies in this category were based on live telephone monitoring by nurses, the
content, complexity and implementation of the interventions varied widely.
Automated Monitoring of Signs and Symptoms—This study is based on automated
monitoring of patients’ signs and symptoms. Monitoring is accomplished by patients entering
data into an electronic communication device with information then downloaded into a secure
website to be reviewed by clinicians at a later time.
In the Weight Monitoring in Heart Failure (WHARF) trial, Goldberg et al enrolled recently
hospitalized patients followed at heart failure specialty clinics to determine the effects of twice
daily electronic home monitoring of symptoms and weight on hospital readmission (19). The
system consisted of an electronic scale placed in patients’ homes with a monitor for patients
to answer questions about symptoms. The home-based system was linked to a computerized
database monitored by trained cardiac nurses employed by Alere®. Cardiac nurses reviewed
data, but responsibility for acting upon the information rested solely with patients’ physicians,
who were updated regularly about patients’ status. No difference in the primary endpoint of
all-cause hospitalization rates was observed (RR 0.85 (95% CI 0.6–1.25)). Interestingly, a 56%
reduction (95% CI 0.22–0.85) in mortality (a pre-specified secondary endpoint) was observed
with use of the telemonitoring intervention.
The WHARF trial demonstrated no benefit in the primary outcome of hospitalization rates.
This study was relatively recent but did not include economic analysis. Despite the proliferation
of systems to support home-based, automated monitoring, there is relatively little evidence to
support their effectiveness.
Automated Physiologic Monitoring—Collection of physiologic data can take a variety
of forms. Benatar et al compared the effectiveness of daily self-monitoring of weight, blood
pressure, heart rate and oxygen saturation with home nurse visits (20). Physiologic monitoring
was performed by patients in their homes, with the information transmitted to a secure internet
site for review by patients’ cardiologists. Home visits were scheduled 3 times per week during
the first week, decreasing in frequency thereafter to 1 visit by the fourth week and further visits
on an “as-needed basis.” The content of these visits included discussion of diet, symptom
recognition and adherence with medications. There was a 40% reduction (95% CI 0.45–0.82)
in heart failure admissions among the telemonitored group compared with the nurse home visit
group. The daily cost of the telemonitoring intervention was reported to be $2.87 and the 6
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month cumulative readmission charges were $223,638 in the telemonitoring group and
$500,343 in the group receiving nurse visits.
This study of automated physiologic monitoring demonstrated reduction in heart failure
hospitalizations and included analyses suggesting that the intervention may be cost-beneficial.
This study met fewer of our quality criteria (2) than studies in the categories discussed above.
Comparisons of 2 or More Methods of Telemonitoring—Given the diversity of
telemonitoring interventions, studies that directly compare the effectiveness of 2 or more
modalities are quite useful. Cleland et al enrolled 426 patients recently admitted for heart failure
in 3 European countries to compare the effectiveness of physiologic monitoring versus nurse
telephone support (8). Physiologic monitoring was performed twice daily in patients’ homes
using automated devices including an electronic scale, sphygmomanometer, and an
electrocardiogram. Each device was linked to a central web server for review by study nurses.
The nurses could make short-term changes in therapy or work through patients’ primary
physicians if long-term therapeutic changes were needed. The intervention in the nurse
telephone support arm consisted of monthly calls by a heart failure specialist nurse to assess
symptoms and medications. Nurses offered advice to patients and provided feedback to
patients’ primary physicians. While outcomes were improved in both intervention arms
compared with usual care, no between-group differences in the primary outcome of days lost
to death or hospitalization were seen in the group receiving physiologic monitoring and the
group receiving telephone support (12.7% versus 15.9% respectively).
Jerant et al randomized 37 patients to receive: video conferencing with an integrated
stethoscope; nursing support by telephone; and usual care (15). The frequency of each
intervention was tailored to meet individual patients’ needs, with the overall goal of monitoring
signs and symptoms as well as patient education. Video conferencing employed a camera to
allow observation of respiratory effort and leg edema and an integrated stethoscope applied to
standard heart and lung auscultation points. Management was deferred to patients’ own
physicians, who were sent summaries and recommendations. While 6-month heart failure
readmission charges were higher in the usual care group compared with the 2 intervention
groups, no differences were seen between the video conferencing and telephone support groups
($5850 versus $7320 respectively). Due to small sample size, relative risks could not be
calculated to compare admissions and mortality between groups.
The 2 studies comparing 2 or more methods of telemonitoring varied in interventions studied,
size and quality – one met all 6 quality criteria, and the other met 4. Although these studies
found telemonitoring to be beneficial compared with usual care, various forms of
telemonitoring appeared equivalent when tested against each other in these two studies. This
finding is striking given that the forms of telemonitoring within each study were quite different
in technical sophistication, intensity and cost. The study by Jerant et al included economic
analyses, demonstrating both forms of telemonitoring intervention to be cost beneficial. Of
note, no incremental benefit was seen with the far more costly video conferencing (1-year cost
$7487, inflation-adjusted cost in 2006 United States dollars $8383) compared with telephone
support (1-year cost $1514, inflation-adjusted cost in 2006 United States dollars $1695). With
a total sample size of only 37 participants, however, it is difficult to draw conclusions about
the relative effectiveness of the interventions.
DISCUSSION
In this review, we have summarized the evidence for interventions based solely on
telemonitoring without any face-to-face component. Based upon this review it appears that the
literature is in evolution and confounded by several factors. Compared with other forms of
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heart failure disease management, there are few large, high quality trials that can be used to
guide policy regarding implementation of telemonitoring, and no data about long-term
sustainability of these programs. High quality data regarding the effectiveness of automated
forms of telemonitoring are especially scarce, despite the proliferation of private companies
offering such services and the potential benefit of this form of telemonitoring in settings with
limited personnel. Rigorous cost-effectiveness analyses with reasonably long-term horizons
are scarce and detailed, prospective cost analyses should be included in future studies of HF
disease management in general, and telemonitoring interventions in particular. Without a clear
understanding of the economic implications of telemonitoring interventions, it will be difficult
to establish informed national policies regarding reimbursement for these programs.
Understanding precisely what makes some telemonitoring interventions effective is critical to
decisions about how this strategy should be applied to populations of heart failure patients.
The data are mixed on whether greater frequency of monitoring leads to better outcomes. The
findings by Benatar et al that daily physiological monitoring was more effective in reducing
hospital readmissions compared with periodic home visits suggests that frequency of
monitoring may be important. However, in the study by Cleland et al, monthly phone calls by
nurses were essentially equivalent (in affecting outcomes) to twice-daily physiologic
monitoring. While the interventions in the DIAL trial and the studies by Dunagan and Cleland
included a component of active patient management, this does not seem to be a distinguishing
feature between effective and ineffective interventions. While 3 out of the 5 telephone-based
monitoring studies demonstrated a benefit, the negative studies by Riegel and DeBusk are
notable. In Riegel’s study of Hispanic patients, the authors point out that nurses had difficulty
reaching patients at various times during the follow-up period because they were moving
among different households or traveling back to Mexico. Nurses therefore focused more on
contacts with family, which may not be as potent as direct patient contact. The DeBusk study
did specifically enroll patients deemed to be low risk for hospital readmission (on the basis of
medical and sociodemographic characteristics), which may explain the negative findings. The
authors also point out that their study participants (all enrolled in a Health Maintenance
Organization) “all had access to high-quality health care, and they used it extensively.” The
negative findings of Goldberg’s study of automated monitoring also require careful
consideration. It is possible that the quality of usual care received by these patients who were
all followed at heart failure specialty clinics left little room for improvement: a “ceiling effect”
similar to the one seen in the study by DeBusk. Since many patients do not have access to heart
failure specialty clinics, there remains a need to investigate other approaches that can be used
in a variety of practice settings.
As in many areas in medicine, telemonitoring is in rapid evolution and appears to be moving
towards more technically sophisticated and invasive forms of interventions. Recently
completed but as yet unpublished trials are employing invasive monitoring of cardiac pressures
with automated transmission of data (21). While preliminary results suggest this approach may
have value in improving outcomes (22), such strategies will have to be evaluated for cost-
effectiveness, scalability, safety, and acceptability to patients. Given the ever-growing number
of patients affected by chronic diseases such as heart failure, the Centers for Medicare and
Medicaid Services and other major payers cannot afford to invest in expensive telemonitoring
interventions for which the incremental increase in cost (compared with less expensive
interventions) is not proportional to an improvement in outcomes. Our review suggests that
telephone-based systems of monitoring are less expensive and appear equally effective when
compared with more complex forms of monitoring (15), though this needs to be confirmed in
larger studies. While the Institute of Medicine’s report “Crossing the Quality Chasm” states
that “[information technology] must play a central role in the redesign of the health care
system,” to improve quality of care for patients with chronic disease such as heart failure (1),
careful consideration of how best to implement such interventions is needed.
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Figure 1.
Literature search and selection process.
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Table 2
Automated Monitoring of Signs and Symptoms
Goldberg
Year published 2003
Country USA
Study design/no. quality criteria met RCT / 5
Sample size/eligibility proportion 280 / NA
Description of study population Recently hospitalized for HF, recruited from
HF centers
Men (%) 68
Mean age (SD) 59 (15)
HF severity 75% NYHA class III, 25% class IV
ACE/ARB at baseline (%) 74
Beta-blocker at baseline (%) 38
Intervention: nature and intensity Twice daily monitoring of symptoms and
weight for 6 months
Primary outcome All-cause hospitalization
All-cause hospitalizations, event rate RR (95% CI) NA 0.85 (0.6–1.25)
HF hospitalizations, event rate RR (95% CI) NA NA
Mortality, event rate RR (95% CI) 11/138 I 26/142 C 0.44 (0.22–0.85)
Eligibility proportion refers to the number of patients screened for participation divided by the number actually enrolled in the study.ACE, angiotensin-
converting enzyme; ARB, angiotensin-receptor blocker; CI, confidence interval; HF, heart failure; NA, not available; NYHA, New York Heart Association;
RCT, randomized controlled trial; RR, relative risk; SD, standard deviation; I, intervention group; C, control group
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Table 3
Automated Physiologic Monitoring
Benatar
Year published 2003
Country USA
Study design/no. quality criteria met Randomized trial / 2
Sample size/eligibility proportion 216 / 0.79
Description of study population Outpatients from 2 academic centers
Men (%) 37
Mean age (SD) 63 (12)
HF severity Mean NYHA class 3.1 (SD 0.26)
ACE/ARB at baseline (%) 75
Beta-blocker at baseline (%) 53
Intervention: nature and intensity For 3 months, daily monitoring of weight,
blood pressure, heart rate and oxygen
saturation compared with home nurse visits
Primary outcome Not specified
All-cause hospitalizations, absolute event rate RR (95% CI) NA NA
HF hospitalizations, event rate RR (95% CI) 38/108 DM 63/108 HNV 0.60 (0.45–
0.82)
Mortality, event rate RR (95% CI) NA NA
Eligibility proportion refers to the number of patients screened for participation divided by the number actually enrolled in the study.
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CI, confidence interval; HF, heart failure; NA, not available; NYHA, New
York Heart Association; RCT, randomized controlled trial; RR, relative risk; SD, standard deviation; DM, daily monitoring group; HNV, home nurse
visits
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